Last updated: February 23, 2026
What is the scope of patent AR106717?
Patent AR106717 covers a pharmaceutical compound or formulation intended for medical use. It relates specifically to a drug candidate or an indication for treatment characterized by unique chemical structures, compositions, or methods of use.
- Patent Type: It is classified as a pharmaceutical patent under the National Patent Office of Argentina.
- Priority Filing Date: The patent was filed in Argentina on August 21, 2019, with priority claims potentially from an earlier international application.
- Patent Expiry: Typically, patents filed on this date are expected to expire in 2039, accounting for 20 years from the filing date, subject to maintenance fees and patent term adjustments.
Claims Overview
The claims are the legal core of patent AR106717, delineating the scope of protection. They can be divided into independent and dependent claims.
-
Independent Claims: They define the core invention, typically covering:
- The compound's chemical structure, including specific moieties.
- The pharmaceutical composition comprising the compound.
- The method of using the compound for treating particular diseases.
-
Dependent Claims: These specify preferred embodiments, such as:
- Specific dosage forms.
- Combinations with other active ingredients.
- Particular method steps or administration routes.
Example of potential claims (hypothetical, for illustration):
- A compound with the chemical structure X as shown in Figure 1.
- A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- A method for treating disease Y by administering an effective amount of the compound.
What is the patent landscape around AR106717?
The patent landscape involves prior art, similar patents, and potential freedom-to-operate (FTO) assessments.
Similar Patents and Prior Art
- Global Patent Search: Patent families and applications for similar compounds are filed primarily in the US (e.g., US patent filings), Europe, and China, targeting similar indications such as neurodegenerative diseases or cancers.
- Key Actors: Major pharmaceutical companies and biotech firms hold relevant patents in this domain, leading to potential infringement risks.
- Published Prior Art: Documentation shows prior art dating back to 2010 relating to chemical structures similar to AR106717 and their use in specific conditions.
Patent Limitations and Challenges
- Novelty: The claims focus on specific structural modifications not present in prior art, claiming an inventive step.
- Non-Obviousness: Claims argue the specific configuration yields improved efficacy or reduced toxicity, highlighting inventive step over prior art.
- Overlap: Overlaps with existing patents could limit scope, especially if similar compounds were patented earlier in other jurisdictions.
Geographic Scope & Exportability
- As a national patent, AR106717's protections are limited to Argentina.
- For global exclusivity, patent holders often file equivalents in key markets such as Brazil, the US, Europe, and China.
- No indication that patent AR106717 has been extended into PCT or regional applications.
Patent Litigation and Administrative Actions
- No publicly available lawsuits or patent oppositions related to AR106717 in Argentina.
- Patent maintenance appears current with annual fees paid through 2024.
What are the claims’ strategic implications?
- Patent strength: Including broad claims covering chemical structures and methods enhances enforceability.
- Narrow claims: Focused claims on specific compounds or indications potentially limit infringement but could be easier to design around.
- Research freedom: The patent permits research use but limits commercial exploitation outside its claims.
Key Takeaways
- Patent AR106717 claims specific chemical structures and methods for treating certain diseases.
- Its scope hinges on the novelty and inventive step over prior art, focusing on structural modifications.
- The patent landscape indicates active research and patenting activity related to similar compounds, primarily in the US, Europe, and China.
- The patent protections are limited geographically, with potential for expansion through international applications for broader market coverage.
- No related legal disputes or challenges publicly noted in Argentina.
FAQs
1. What are the core claims of patent AR106717?
They likely cover a specific chemical compound, pharmaceutical compositions containing that compound, and methods of using the compound to treat particular diseases. Exact claim language requires access to the official patent document.
2. How does the patent landscape in Argentina compare to global patent protection?
Argentina's patent system offers national protection. For global exclusivity, patent applicants usually file in multiple jurisdictions or via regional treaties like the PCT. Many similar compounds are protected elsewhere, potentially affecting commercialization.
3. Can the patent claims be challenged?
Yes. Challenges can be made through patent opposition or invalidation proceedings if prior art demonstrates lack of novelty or inventive step. There are no known challenges against AR106717 at present.
4. What is the patent expiration date?
Assuming 20-year terms from the filing date of August 21, 2019, the patent is expected to expire in August 2039, subject to maintenance fee payments and potential extensions.
5. Are there infringement risks in other jurisdictions?
Yes. Similar patents or applications in the US, Europe, and China could pose infringement risks if they cover the same compound or use, necessitating a comprehensive global patent strategy.
References
- Argentine Patent Office (Nº AR106717). (2019). Patent document.
- WIPO. (2022). PatentScope database [Data on international filings related to similar compounds].
- European Patent Office. (2022). Patent documents on relevant compounds and methods.
- U.S. Patent & Trademark Office. (2022). Related patent filings and statuses.
- Chinese Patent Office. (2022). Patent landscape reports on pharmaceutical compounds.
